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Abstract: Stem cell therapies may be valuable in treatment of inflammatory bowel disease 
(IBD). Here we focus on two very different types of stem cells – hematopoietic stem cells 
and mesenchymal stem cells. Myeloablation and hematopoietic stem cell transplantation 
alter host immune response by reconstituting the recipient’s blood cell lines with donor cells. 
Autologous hematopoietic reconstitution may “reboot” mucosal immunity to a normal baseline 
state, but does not alter any underlying genetic predisposition to IBD. In contrast, allogeneic 
hematopoietic transplantation reconstitutes all blood lineages from a tissue-matched donor 
who presumably does not have a genetic predisposition to IBD. Compared with autologous 
hematopoietic transplantation, allogeneic hematopoietic transplantation carries a much greater 
risk of complications, including graft-versus-host disease. Mesenchymal stem cells can give rise 
to cartilage, bone and fat in vitro, but do not reconstitute hematopoiesis after transplantation. 
Systemically infused mesenchymal stem cells appear to favorably downregulate host immune 
responses through poorly understood mechanisms. In addition, mesenchymal stem cells may 
be applied topically to help close fistulas associated with Crohn’s disease. For all of these stem 
cell therapy applications for IBD, only cases and small series have been reported. Larger clinical 
trials are planned or ongoing.
Keywords: inflammatory bowel disease, Crohn’s disease, stem cell therapy, bone marrow 
transplant, mesenchymal stem cell
Introduction
Stem cells are defined by asymmetric cell division, self-renewal, and multilineage 
differentiation. Stem cell-based therapies hold great promise for many diseases. 
Embryonic stem cells (ES) are pluripotent cells derived from the preimplantation 
embryo, capable of forming tissues from all three germ layers in vitro and in vivo. The 
ability of ES cells to expand in culture and differentiate to specific phenotypes under 
various culture and growth factor conditions makes them an attractive source of cells 
for therapy. Induced pluripotent stem cells (iPS) can be derived from adult somatic 
cells forced to reprogram to an ES-like state in culture. Like ES cells, iPS cells can be 
redirected toward other phenotypes under specific culture conditions. iPS cells are not 
derived from embryos, avoiding ethical concerns regarding the use of human embryos. 
iPS cells can also be made from any patient, allowing the production of patient-specific 
and disease-specific cells for research and treatment. Undifferentiated ES and iPS 
cells can both give rise to teratomas after transplantation, so complete eradication of 
undifferentiated cells is a critical step toward the clinical use of cell therapy when ES 
or iPS cells are used to produce differentiated cells for therapy.Clinical and Experimental Gastroenterology 2010:3 
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In contrast, adult stem cells are derived from mature 
organs and are much more limited in differentiation potential 
compared with ES or iPS. As such, adult stem cells might 
be better considered as multipotent “progenitor” cells rather 
than stem cells. However, the language of “adult stem cells” 
is well established so we will follow this convention. The best 
understood adult stem cells are hematopoietic stem cells, 
which can be enriched from the bone marrow or collected 
from peripheral blood. After transplantation into properly 
conditioned recipients, hematopoietic stem cells reconstitute 
and maintain all the mature blood lineages. Bone marrow 
transplantation has become an accepted treatment for leuke-
mias, lymphomas, and other blood diseases. For patients fac-
ing otherwise incurable and fatal blood diseases, the potential 
benefits of bone marrow transplantation outweigh the risks 
of infection, hemorrhage and graft-vs-host disease.
Mesenchymal stem cells (MSC) are an entirely different 
type of adult stem cell. MSC can be derived from bone mar-
row, fat, or other tissues. MSC are perhaps more restricted in 
their differentiation potential to mesodermal tissues such as 
fat, cartilage and bone. Transplanted MSC do not reconsti-
tute hematopoietic lineages, but can alter the host immune 
response. In this review we will consider cell therapy based 
on hematopoietic stem cell transplantation or MSC infusion 
for the treatment of Crohn’s disease (CD) and ulcerative 
colitis (UC). To date, there are no reports of therapeutic 
interventions for inflammatory bowel disease (IBD) using 
ES or iPS-derived cells.
In patients with IBD, mucosal ulceration and inflamma-
tion may cause abdominal pain, chronic diarrhea, anemia 
and malnutrition. In UC, the inflammation is generally 
limited to the mucosa of the colon. In contrast, the inflam-
mation in CD affects all layers of the bowel wall and is 
not limited to the colon. The transmural inflammation 
of CD may lead to bowel obstruction or fistula forma-
tion requiring surgical intervention. In both conditions, 
chronic inflammation is associated with an increased 
risk of intestinal malignancy. IBD may be considered an 
autoimmune disease, resulting from inappropriate immune 
reactivity against one’s own tissues in the digestive tract. 
The mainstay of clinical treatment is a combination of 
anti-inflammatory agents such as 5-aminosalicylates and 
immunosuppressive medications, including corticoste-
roids and immunomodulators such as azathioprine. Newer 
agents, including monoclonal antibodies directed against 
tumor necrosis factor or alpha-4-integrin, are available for 
patients who are unable to achieve remission with standard 
immunosuppression. Despite treatment, the morbidity and 
cost of IBD remain high. Corticosteroids are not effective 
for maintaining remission of IBD and induce well-known 
adverse side effects, including weight gain, diabetes and 
osteoporosis. Immunosuppression carries significant risk 
for infection by opportunistic pathogens. New treatment 
approaches are needed.
Recent advances reveal a primary role of dysregula-
tion of the immune system in the pathogenesis of IBD. 
Sophisticated genome-wide association studies implicate 
maladaptive signaling of a number of cytokines and their 
receptors.1 Examples include variants in genes encoding 
NOD2/CARD15, IL23R, TNFSF152,3 and IL-10R.4 Mouse 
models of IBD may be categorized as chemical, genetic, 
immunologic, and spontaneous.5 Each approach offers 
different strengths and limitations, but it is now clear that 
the mucosal immune response to luminal antigens plays a 
central role in the pathogenesis of IBD. Genetically suscep-
tible mice reared under germ-free conditions fail to develop 
disease, demonstrating the essential role of luminal flora. 
Classic experiments demonstrated that IBD-like illness can 
be transmitted by adoptive transfer of pathogenic T cells in 
mice.6 In a susceptible host, inappropriate and prolonged 
immunologic response to mucosal flora results from failure 
of regulatory T cells to restrict the activity of self-reactive 
effector T cells.7–9 While bone marrow transplant from IL-10 
knockout mice into wild-type recipients does not transfer 
IBD, colitis can be markedly ameliorated in IL-10 knockout 
mice after bone marrow transplantation with normal bone 
marrow. The improvement of colitis after transplantation of 
normal bone marrow into IL-10 deficient mice appears to be 
due to engraftment of donor-derived subepithelial myofibro-
blasts.10 A possible human case of adoptive transfer of IBD 
was reported in a patient undergoing allogeneic bone marrow 
transplant (BMT) for Hodgkin’s disease. Though the patient 
had no prior history of IBD, she developed acute fulminant 
Crohn’s colitis 6 months after allogeneic BMT. While the stem 
cell donor had no personal or family history of IBD, genomic 
analysis showed that the donor, but not the recipient, carried 
a CD-associated polymorphism in the NOD2/CARD15 
gene. Donor and recipient also had numerous HLA class III 
haplotype mismatches at the IBD3 locus.11
While immunosuppression can reduce and control inflam-
mation, it fails to fundamentally interrupt the underlying 
disease process. Advances in bone marrow transplantation 
now allow the ablation and replacement of the hematopoietic 
system with autologous or allogeneic hematopoietic stem 
cells. In some cases, this appears to effectively interrupt the 
cycle of inflammation by “resetting” the immune system with Clinical and Experimental Gastroenterology 2010:3 
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naïve cells. Another novel treatment approach is the use of 
mesenchymal stem cells (MSC), typically derived from bone 
marrow or fat, as immunosuppressive agents to downregulate 
mucosal immune reactivity.
There are many case reports and small retrospective 
series of patients experiencing dramatic improvement in 
chronic non-IBD autoimmune conditions following autolo-
gous or allogeneic hematopoietic stem cell transplantation 
for unrelated malignancies. These unexpected successes led 
to trials of hematopoietic stem cell transplantation (mostly 
autologous) as a salvage therapy for autoimmune diseases 
refractory to standard immunosuppressive therapy.12 Simi-
larly, unexpected remission of IBD in patients undergoing 
BMT for other reasons inspired examination of BMT as a 
therapy for IBD.
This review will focus on two “stem cell therapy” 
approaches to treating IBD by fundamentally altering the 
mucosal immune response: bone marrow hematopoietic 
stem cell transplantation and mesenchymal stem cell 
transplantation.13
Autologous bone marrow stem cell 
transplantation for IBD
The first report of remission of IBD after autologous hema-
topoietic stem cell transplantation was that of a 41-year-old 
woman with more than 20 years of fistulizing CD, who 
subsequently developed non-Hodgkins’ lymphoma (NHL). 
Her NHL was treated with chemotherapy and autologous 
bone marrow stem cell rescue. Six months after BMT, the 
lymphoma was in remission and she was free of CD symp-
toms for the first time in many years. The authors speculated 
that the improvement in her CD resulted from the BMT, and 
concluded that CD need not be an absolute contraindication 
to autologous BMT.14 Several more anecdotal reports 
of clinical remission of IBD in patients who underwent 
chemotherapy and autologous hematopoietic stem cell rescue 
for coincidental malignancies followed (Table 1).
Based in part on the successful treatment of patients with 
CD and coincident malignancies using stem cell mobiliza-
tion, myeloablation, and autologous stem cell rescue, this 
approach has been attempted as salvage therapy for IBD 
in patients who did not have malignancies (Table 2). The 
patients reported in those studies had active, refractory CD 
with multiple complications. Oyama et al15 reported clinical 
remission in 11 of 12 patients, while Cassinotti et al16 reported 
remission in 3 of 4 patients. This approach effectively takes 
immunosuppression to the extreme, completely ablating the 
immune system and reconstituting it with hematopoietic 
stem cells which give rise to naïve lymphoid and myeloid 
cells. The effectiveness of this approach is consistent with the 
model that dysregulation of T cell activity against mucosal 
self antigens plays a major role in the pathogenesis of IBD. 
The lack of recurrent disease after autologous BMT indicates 
that interruption of the pro-inflammatory T cell response is 
sufficient to break the maladaptive cycle of self-reactivity. 
However, the number of patients reported is very small and 
there were no controls. The success of this approach might 
be overestimated by reporting bias, since therapeutic failures 
and treatment-related adverse events may be less frequently 
reported. One patient with remission of CD following autolo-
gous BMT for NHL experienced relapsed of her CD 8 years 
later, indicating that long-term follow up is essential.17
Despite these limitations, the clinical improvements are 
very impressive in a group of patients refractory to even the 
best available standard treatment. While the risk of morbidity 
and mortality from sepsis and hemorrhage during the interval 
between myeloablation and autologous hematopoietic reconsti-
tution is significant, a carefully designed, prospective clinical 
Table  Case reports of iBD outcomes after myeloablation and autologous stem cell transplantation for coincidental malignancy
Disease (n) Indication Conditioning Graft IBD outcome Ref
CD (n = 1) NHL Chemo BMSC 3 × 10e8/kg remission at 6 mos  
Off immunosuppression
14
UC (n = 1) Breast cancer Chemo mPBSC ?dose remission  2 yrs 67
CD (n = 1) Breast cancer Chemo mPBSC ?dose remission  2 yrs 67
CD (n = 1) T cell NHL Chemo mPBSC 9.8 × 10e8/kg remission 7 yrs  
Off immunosuppression
68
CD (n = 1) Hodgkin’s Chemo mPBSC ?dose remission  3 yrs  
Off immunosuppression
69
CD (n = 1) AML Chemo TBi BMSC, mPBSC ?dose remission  6 yrs  
Off immunosuppression
70
Abbreviations: See list in text.Clinical and Experimental Gastroenterology 2010:3 
Swenson and Theise Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
trial is warranted for patients who have failed conventional 
therapy and are willing to accept the risk of autologous 
BMT. A multicenter, prospective, randomized Phase III trial, 
“Autologous Stem Cell Transplantation in Crohn’s Disease 
(ASTIC)” is underway in Europe. All patients enrolled in this 
trial will undergo stem cell mobilization and leukapheresis. 
Patients will then be randomized to undergo either immediate 
or delayed (one year) immunoablation and autologous stem 
cell transplantation. Patients in the delayed transplant group 
will continue to receive optimal conventional care for CD. 
This design allows all patients in the trial the opportunity to 
undergo autologous BMT, with the delayed transplant group 
serving as controls. The immediate transplant group will be 
compared with the delayed transplant group in terms of disease 
remission, defined as a CD activity index of 150 without 
steroids or immunosuppressive drugs and no mucosal erosion 
or ulceration at ileocolonoscopy, and no definite evidence of 
small bowel Crohn’s Disease on barium studies. A total of 
48 patients will be recruited. As of July, 2009, 14 patients had 
been enrolled, 7 of whom have undergone autologous BMT. 
Additional details are available at http://www.nottingham.
ac.uk/icr/astic/index.php. It is not clear whether autologous 
BMT will benefit patients with germline polymorphisms 
in CD-susceptibility genes, which will not be altered by 
autologous BMT. This issue will need to be considered in the 
outcome analysis of the clinical trials.
Allogeneic bone marrow stem cell 
transplantation
There have been numerous reports of fortuitous resolution of 
non-IBD autoimmune diseases such as rheumatoid arthritis 
and psoriasis in patients who underwent allogeneic BMT 
for leukemias.18–21 The first reported case of a patient with 
UC undergoing allogeneic BMT was a 39-year-old woman 
with a 12-year history of UC, who subsequently developed 
AML. Following induction and consolidation treatment with 
chemotherapy, she received an allogeneic BMT from her 
HLA-matched brother. Four years later, her AML remained 
in remission and her UC was clinically inactive.20 The first 
reported case of a patient with CD undergoing allogeneic 
BMT was a 35-year-old man with stricturing CD who sub-
sequently developed acute myelocytic leukemia (AML). The 
AML was treated with multiagent chemotherapy and the 
patient underwent allogeneic BMT from his HLA-matched 
brother. His post-transplant course was complicated by mild 
GVHD of the skin, which responded to corticosteroids. All 
immunosuppression was tapered off over the next 7 months 
and he remained in remission of both AML and CD for at 
least 8 years.22
Two retrospective series of patients with both IBD 
and leukemia who underwent allogeneic BMT reported 
a substantial number of remissions from IBD (Table 3). 
Lopez-Cubero23 reported 6 CD patients who underwent 
allogeneic BMT for CML or AML. All were treated with 
multiagent chemotherapy for leukemia. Transplant condi-
tioning regimens included cyclophosphamide and total body 
irradiation. Allogeneic donor cells were HLA-matched in 
all but one case and were not T cell-depleted. CD activity 
could not be assessed in the patient with AML, who died 
from sepsis 97 days after transplant. Of the five survivors, 
four achieved symptomatic remission from CD over 4 to 
15 years of follow-up. Both acute and chronic GVHD of the 
Table  Case reports and small series of inflammatory bowel disease outcomes after myeloablation and autologous stem cell 
transplantation for Crohn’s disease
Disease (n) Conditioning Graft IBD outcome Ref
CD (n = 1) Cyc T-cell depleted  
CD34+ mPBSC  
6.4 × 10e6/kg
remission for 9 mos  
recurrent aphthous ulcers  
Maint. corticosteroids and MTX
71
CD (n = 1) Cyc ATG T cell-depleted  
CD34+ mPBSC  
3.4 × 10e6/kg
Symptomatic remission for 5 mos  
Endoscopic and pathologic improvement, off 
immunosuppression
72
CD (n = 12) Cyc ATG T-cell depleted  
CD34+ mPBSC  
2 × 10e6/kg
remission in 11 of 12  
7–37 mos follow-up  
Corticosteroids tapered over 2–6 mos
15
[*2 of these subjects were already reported by Burt et al in 2003]
CD (n = 1) Not stated Not stated remission for 8 yrs followed by relapse 17
CD (n = 1) Not stated Not stated remission for 6 yrs 73
CD (n = 4)  Cyc ATG  mPBSC ?dose  remission in 3 of 4 11–20 mos follow-up  
Off immunosuppression
16 
Abbreviations: See list in text.Clinical and Experimental Gastroenterology 2010:3 
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skin and/or liver were noted in the same four patients who 
achieved remission from CD.
Ditschkowski and colleagues24 reported a retrospective 
review of 7 CD patients and 4 UC patients who underwent 
allogeneic BMT for AML, CML or myelofibrosis. Five of 
the CD patients had a history of fistula or luminal stenosis. 
Prior to BMT, five patients had inactive IBD, while six were 
described as having mild or low activity based on symp-
toms, endoscopic findings, or histology. The chemotherapy, 
myeloablative conditioning regimen and transplantation 
protocols varied. One patient died within the first year after 
transplant from pulmonary fungal infection. Of the 10 sur-
vivors, only 1 had mild CD after transplant, while the other 
9 achieved remission from IBD during a median followup 
period of 34 months (range 3 to 117 months). Eight patients 
developed Grade I or II GVHD, which was managed success-
fully with steroids. None developed severe or chronic GVHD. 
A very recent report identified loss-of-function mutations in 
IL10-RA and IL-10RB in patients with early onset, severe 
enterocolitis.4 One patient with a mutation in the IL1-10RB 
gene suffered from severe anocutaneous fistula, refractory 
to standard therapy. He underwent allogeneic BMT from 
an HLA-matched sibling who did not carry the IL-10RB 
mutation. He achieved full donor hematopoietic chimerism, 
and his post-transplant course was marked by mild GVHD, 
treated successfully with corticosteroids. More than 1 year 
after transplantation, his IBD was fully in remission.4 In 
the case where the genetic mutation underlying IBD could 
be clearly identified, autologous transplantation would not 
have been helpful. An HLA-matched sibling donor without 
that mutation was available, so allogeneic transplantation 
was both ethical and practical. To our knowledge, there are 
no planned prospective clinical trials of allogeneic BMT in 
IBD, presumably due to concerns for the greater incidence of 
transplant-related complications in allogeneic BMT recipi-
ents compared with autologous BMT.
Immunomodulatory stem cell 
therapy with MSC
MSC are a fibroblast-like cell population, first recognized as 
a population of non-hematopoietic bone marrow cells which 
adhere to plastic tissue culture dishes.25 MSC are a multi-
potent stem cell population, capable of differentiating into 
osteocytes, chondrocytes and adipocytes under appropriate 
culture conditions.26 In an attempt to standardize the definition 
of MSC, minimal criteria were proposed (Table 4).27 MSC 
have now been isolated from a wide variety of adult tissues,28 
though most attention has focused on MSC derived from bone 
marrow or fat. A great deal of interest has focused on poten-
tial therapeutic uses for MSC due to their reported ability to 
suppress inflammation and promote tissue healing.29
Several potential mechanisms have been proposed for 
the potential immunomodulatory effects of MSC, including 
release of soluble factors (cytokines, chemokines, growth 
factors), induction of cell cycle arrest in pro-inflammatory 
Table  Minimal criteria for defining multipotent mesenchymal 
stem cells27
1.   Adherent to plastic under standard culture conditions
2.  Express CD105, CD73 and CD90
3.    Lack expression of CD45, CD34, CD14 or CD11b, CD79a or CD19 
and HLA-Dr
4.  Differentiate to osteoblasts, adipocytes and chondroblasts in vitro
Abbreviations: See list in text.
Table  Case reports and small series of inflammatory bowel disease outcomes after myeloablation and allogeneic stem cell 
transplantation
Disease (n) Indication Conditioning Graft IBD outcome Ref
UC (n = 1) AML Not stated Not stated remission 4 yrs 20
CD (n = 1) AML Chemo AlloBMT CSA  
for 7 mos  
Steroids for 2 mos
remission 7 years off  
immunosuppression
22
CD (n = 5) CML Chemo TBi AlloBMT, varied remission in 4 of 5  
patients followed for  
4–15 yrs
23
(A sixth CD patient with AML died 97 days after alloBMT; recurrent CD could not be evaluated)
CD (n = 7)  
UC (n = 4)
AML, CML, MF varied AlloBMT, varied remission in 9 of 10  
survivors
24
CD (n = 1) iBD, iL-10rB mutation Chemo Sibling  AlloBMT remission 1 yr 4
Abbreviations: See list in text.Clinical and Experimental Gastroenterology 2010:3 
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lymphocytes, and induction of T cell apoptosis.30 A likely 
role for nitric oxide in MSC-mediated immunosuppression 
has been recently identified.31 In addition to modulating 
immune activity, MSC may also regulate wound healing 
through direct or indirect interactions with resident tissue-
committed stem cells.32 The immunomodulatory and wound 
healing effects of MSC provide the rationale for investigation 
of their therapeutic value in autoimmune and inflammatory 
disease conditions.
Efforts to improve the engraftment of transplanted 
human hematopoietic stem cells by coinfusion of MSC 
met with variable success but little persistent stromal 
chimerism, so the mechanism of benefit is unclear.33–36 
Many reports claim that donor MSC need not be immu-
nologically compatible with the recipient because they are 
non-immunogenic,37 though there is some evidence to the 
contrary.38 Much of the evidence for immunosuppressive 
effects of MSC is based on in vitro work, which may not 
translate to in vivo efficacy.
Nonetheless, there are numerous reports of beneficial 
effects of MSC in animal models of autoimmune disease.39,40 
The mouse myelin oligodendrocyte glycoprotein 35–55 
experimental autoimmune encephalomyelitis (EAE) model 
shares features with human multiple sclerosis. Using the EAE 
model, syngeneic MSC administration was shown to ame-
liorate neurologic and histologic abnormalities by inducing 
T cell anergy, but only when the MSC were administered early 
in the course of disease.41 In a similar model of EAE, MSC 
administration reduced inflammation and demyelination 
through induction of T cell anergy. The infused MSC were 
not found in the central nervous system, indicating that the 
beneficial effect may have been achieved through immuno-
modulation rather than engraftment.42 MSC therapy has also 
been reported to exert a protective effect in mouse models of 
rheumatoid arthritis43,45 and diabetes.46,47
What is the fate of transplanted 
MSC in vivo?
Systemically infused MSC appear to migrate toward sites 
of injury and inflammation. The mechanism by which MSC 
find their way is not fully understood and likely varies among 
tissues, but involves interactions between chemokines and 
their receptors (reviewed in).29,48 The goal of developing 
MSC for therapy requires understanding of the fate of 
transplanted cells, which depends on the dose and route of 
administration. Few studies have addressed this concern 
directly. Systemic administration may be sufficient if MSC 
can home to damaged tissues, but local administration may 
be necessary if high level tissue engraftment is required for 
therapeutic effect.
To investigate this issue, 111In-labeled syngeneic rat bone 
marrow MSC were expanded in culture, delivered to normal 
rats by intraarterial, intravenous or intraperitoneal injection, 
and followed by whole-body gamma imaging. Immediately 
after administration, tracer localized mostly in lungs and 
liver. After 48 hours, most of the tracer appeared in the liver.49 
Major limitations of this approach are that individual organs 
were not examined in detail, and live donor cells were not 
distinguished from dead cell debris being cleared by the 
reticuloendothelial system.
Using a very sensitive PCR DNA ELISA assay, Devine 
et al50 showed that gene-marked autologous or allogeneic 
bone marrow MSC could be detected in baboon bone 
marrow for as long as one year after systemic infusion. 
In subsequent investigations, gene-marked bone mar-
row MSC could also be detected by PCR in the digestive 
tract, liver, pancreas, lung kidney and skin of recipient 
baboons from 9 to 21 months after intravenous infusion. 
The engraftment of gene-marked cells was estimated from 
0.1% to 2.7%, but histologic localization of MSC-derived 
cells was not reported.51
Another approach to monitoring MSC trafficking after 
transplantation is to label cells in culture with iron par-
ticles and follow their distribution in vivo using magnetic 
resonance imaging (MRI). Iron particles are phagocytosed 
by MSC or hepatocytes and stably retained without overt 
toxicity. Iron-labeled cells can be directed to desired sites of 
engraftment, such as the liver, using an externally-applied 
magnetic field.52 Using this approach, single MSC can be 
detected by MRI in the liver after intrasplenic injection.53 
Tracking of infused MSC using MRI has not been reported 
in models of IBD.
Human MSC therapy for GVHD
Graft versus host disease (GVHD) in recipients of allogeneic 
BMT results from response of the donor-derived immune 
cells to host antigens. GVHD typically affects the skin, 
GI tract and liver, and often requires immunosuppression. 
Evidence from animal models suggests that MSC derived 
from adipose tissue can reduce GVHD.54 Coinfusion of 
human MSC with HLA-identical hematopoietic stem cells 
at the time of transplantation may reduce acute and chronic 
GVHD.55 The immunomodulatory effects of MSC may 
therefore provide beneficial effects on acute GVHD and also, 
thereby, points to the possibility that similar mechanisms 
might improve immune-mediated injury in IBD or modulate Clinical and Experimental Gastroenterology 2010:3 
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GVHD if administered to IBD patients receiving allogeneic 
transplants for that disease.
The first reported case of MSC therapy for severe acute 
GVHD was that of a 9 year-old boy with ALL, who under-
went BMT from an unrelated HLA-matched donor. His 
course was complicated by Grade IV GVHD, refractory to 
immunosuppression. He was treated with unmatched bone 
marrow MSC from his mother, administered in two separate 
systemic infusions. The patient experienced a gradual but 
dramatic clinical improvement over the next several months 
and remained asymptomatic of gastrointestinal GVHD 1 year 
after transplantation.56
In September, 2009 Osiris Therapeutics reported in a 
press release preliminary results of a Phase III double-blind, 
placebo-controlled trial of human MSC for steroid-refractory 
GVHD or as a first-line therapy for GVHD after allogeneic 
BMT. Among the patients with steroid-refractory GVHD 
of the gastrointestinal tract or liver, there was a significant 
improvement in GVHD. However, the primary end point 
(durable complete response) was not met.
Potential benefit of MSC in animal 
models of colitis
The ability of MSC to induce tolerance has been investigated 
in animal models of immune-mediated inflammatory bowel 
diseases. Foxp3 mutant mice develop autoimmune disease 
affecting the small bowel due to failure to regulatory T cells 
to eliminate self-reactive T cell clones. Administration of syn-
geneic MSC ameliorated inflammatory disease in the ileum. 
Donor cells were detected in lymphoid tissue in the gut rather 
than in the epithelium, consistent with a model of immunoregu-
lation by infused MSC, rather than epithelial engraftment.57
In the trinitrobenzene sulfonic acid (TNBS) model of 
colitis, intraperitoneal delivery of human or murine adipose-
derived MSC improved diarrhea, body weight, histology 
and survival, in part by downregulating inflammatory cyto-
kines and upregulating IL-10.58 Similarly, human or murine 
adipose-derived MSC abrogated diarrhea, weight loss, while 
improving histology and survival in the dextran sulfate 
mouse model of colitis, also through downregulation of pro-
inflammatory cytokines and upregulation of IL-10.59
Human MSC therapy for IBD
Modest improvements in CD activity index and endoscopic 
appearance of CD were reported in abstract form in a small 
series of patients undergoing autologous systemic MSC 
treatments. Adverse effects were minimal, so the authors 
concluded that MSC therapy is at least safe and feasible.60 
The trial is ongoing.
Osiris Therapeutics is testing an allogeneic human MSC 
product (OTI-010, Prochymal) for use in stem cell therapy 
treatments for GVHD and CD. A Phase II, randomized, mul-
ticenter, open-label pilot trial of OTI-010 for CD refractory 
to standard therapy began in 2005. Patients continued their 
standard treatment regimen for CD during the trial. In 2006, 
Osiris reported in a press release that CD patients treated 
with intravenous MSC (n = 9) had a significant decrease 
in CD activity index, from 341 to 236, 4 weeks after treat-
ment. Three of the 9 patients had clinical response within 
14 days. The trial was very small and lacked controls, but 
the MSC treatment was safe and well tolerated. A Phase III 
trial is planned.
Local MSC delivery to enhance 
healing of enterocutaneous fistula
Perianal fistulae resulting from CD can be very difficult to 
treat effectively, leading to pain, distressing leakage, abscess 
formation and reduced quality of life. Medical treatment 
with 6-mercaptopurine, metronidazole or Infliximab is 
often unsuccessful. Surgical treatment may be complicated 
by recurrence or anal incontinence. The ability of MSC to 
differentiate to a stromal phenotype led to investigation of 
adipose-derived autologous MSC to enhance healing of peri-
anal fistula. In a Phase I study, 8 fistulae in 4 CD patients were 
treated with local injection of adipose-derived autologous 
MSC and fibrin glue. After 8 weeks, 6 of the 8 fistulae had 
epithelialized, while two continued to drain.61
In a Phase II study, 49 patients with perianal fistula were 
randomized to undergo attempted fistula closure using fibrin 
glue, with or without adipose-derived MSC. Fistula healing 
occurred in 71% of the patients receiving MSC with fibrin 
glue, compared with just 16% of patients treated with fibrin 
glue alone.62 Whether the MSC directly engraft the fistula 
tract or simply promote closure could not be assessed because 
the cells were autologous. Adverse events were generally 
unrelated to the treatment, except in the case of one non-IBD 
patient who developed a perianal abscess after application 
of fibrin glue without MSC. Phase III trials are under way 
in Europe.63
Potential risks of stem cell therapies
The risks of autologous or allogeneic hematopoietic stem 
cell transplantation are well known, and include hemorrhage, 
sepsis and graft-vs-host disease. Allogeneic bone marrow Clinical and Experimental Gastroenterology 2010:3 
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donors are thoroughly screened to prevent transmission of 
infectious diseases, though acute infections may be missed 
and laboratory errors are always possible. The production of 
clinical-grade human MSC for therapy also requires rigorous 
exclusion of infectious bacterial and viral diseases. Unlike 
hematopoietic cells, MSC must be expanded in culture under 
Good Manufacturing Process conditions, with rigorous 
quality controls. In published reports, human MSC were 
prepared from autologous donors or from “normal” alloge-
neic donors without further description. It would appear that 
the risk of infectious disease or malignancy with autologous 
MSC therapy should be low. As with allogeneic hematopoi-
etic or whole-organ transplantation, there is a small risk of 
transmission of malignancy from donor to recipient. MSC 
themselves may give rise to tumors, though evidence for this 
is limited. In one report, mouse bone marrow MSC trans-
duced with nonviral transposons endoding firefly luciferase 
or DsRed2 for the purpose of cell tracking were infused 
along with whole bone marrow into irradiated recipients. 
Unexpectedly, several of the mice developed sarcomas 
of MSC origin in the lung or extremity.64 Human MSC 
transduced with telomerase acquired a malignant phenotype 
during long-term culture, through loss of Ink4a locus 
and acquisition of activating mutations in K-ras.65 Mouse 
MSC spontaneously transform in culture and contribute to 
fibrosarcomas in vivo, in part through acquisition of point 
mutations in p53.66 These reports suggest that MSC-derived 
tumor formation may be a concern, and long-term MSC 
culture is best avoided. Suppression of GVHD by allogeneic 
MSC may also be coincident with reduction in the beneficial 
graft-vs-tumor effect, therefore it is essential to follow the 
long-term incidence of hematologic disease recurrence in 
patients treated with MSC.
Conclusions
Autologous or allogeneic bone marrow transplant therapy 
for refractory IBD remains experimental. This approach 
should be limited to patients with severe disease who have 
exhausted standard treatment options, and is best performed 
in the context of an appropriately designed clinical trial. 
Systemic immunomodulatory MSC therapy does not appear 
to establish long-term engraftment in the recipient, and does 
not require additional immunosuppression. Whether systemic 
MSC therapy provides long-term remission of IBD remains 
to be determined in a clinical trial. Phase I and II studies 
have not raised concerns for safety, particularly with regard 
to tumor formation. Local or topical application of MSC to 
enhance healing appears to be a promising approach to the 
very difficult clinical management of CD fistula which should 
be investigated further in clinical trials.
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